Our extensive experience in health technology assessment (HTA) through providing strategic advice and guiding evidence generation to support submissions to UK HTA bodies, enables us to provide you with a tailored solution to reimbursement and patient access.
From Early Access to Routine Reimbursement: How Does the SMC Ultra-Orphan Pathway Address Evidence Gaps to Support Reimbursement Decisions?